Welcome to the Lilly Scientific Information Page for AAIC® 2025
Alzheimer's Association International Conference®
Toronto, Canada
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support.
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To receive the latest science and innovation, please be sure to follow us on LinkedIn.
Disclosures
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Nalin Payakachat
- Molecule(s): Solanezumab
Alzheimer’s Disease (AD) Progression and Healthcare Resource Utilization (HRU) in Preclinical AD
Trial(s) Overview:
A4 (Anti-Amyloid Treatment in Asymptomatic AD)
NCT02008357
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Diana Svaldi
- Molecule(s): Donanemab
Head-to-Head Comparison of Susceptibility-Weighted Imaging and T2*-Weighted Gradient-Recalled Echo MRI Sequences to Detect ARIA-H in the TRAILBLAZER-ALZ 6 Trial of Donanemab
Trial(s) Overview:
TRAILBLAZER-ALZ 6 (NCT05738486)
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Drew Butkowski
- Molecule(s): Donanemab
Donanemab Physiologically Based Pharmacokinetic Model Coupled with Natural Life Cycle Model for Amyloid Plaque Aggregation to Predict Target CSF and ISF Concentrations Associated with Amyloid Plaque Reduction
Trial(s) Overview:
I5T-MC-AACD (NCT02624778)
TRAILBLAZER-ALZ (NCT03367403)
TRAILBLAZER-ALZ 2 (NCT04437511)
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Min Jung Kim
- Molecule(s): Donanemab, Flortaucipir
Tau PET and Plasma P-tau217 as Independent and Synergistic Predictors of Clinical Progression in Early Symptomatic AD Patients With Amyloid and Tau Pathology
Trial(s) Overview:
TRAILBLAZER-ALZ 2 (NCT04437511)
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Ivelina Gueorguieva
- Molecule(s): Donanemab
Comparable Cumulative Exposure and Amyloid Reduction Following Donanemab Standard and Modified Titration Dosing in Participants with Early Symptomatic Alzheimer’s Disease from TRAILBLAZER-ALZ 6
Trial(s) Overview:
TRAILBLAZER-ALZ 6 (NCT05738486)
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Xavier Taylor
- Molecule(s): Not Applicable
Investigating the Cascade of Immunological and Vascular Events in Amyloid Immunotherapy
Trial(s) Overview:
Not Applicable
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Caroline Casey
- Molecule(s): Not Applicable
Characteristics and Staging of Patients with Alzheimer’s Disease: Real-World Data from the United Kingdom
Trial(s) Overview:
Not Applicable
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Sam Burnham
- Molecule(s): Lilly SP-X P-tau217 plasma assay
Impact of the Lilly SP-X P-tau217 Plasma Assay on Management of Patients with Cognitive Impairment: Results of a Clinical Utility Study in an Ethnically and Racially Representative Cohort, Lilly J4Y-MC-B002
Trial(s) Overview:
J4Y-MC-B002
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Amanda Morris
- Molecule(s): Donanemab, Flortaucipir
Characterizing Early Symptomatic AD Patients by Visual and Quantitative Tau Profiles
Trial(s) Overview:
TRAILBLAZER-ALZ 2 (NCT04437511)
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Zachary Sheff
- Molecule(s): Not Applicable
Estimating Preclinical Alzheimer’s Disease Populations by P-tau217 in the United States, Japan, Germany, and China
Trial(s) Overview:
Not Applicable
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Vikas Kotari
- Molecule(s): Donanemab, Flortaucipir, Solanezumab
Flortaucipir Patterns in Preclinical Alzheimer’s Disease: An Evaluation of TRAILBLAZER-ALZ 3 Baseline Data
Trial(s) Overview:
LEARN (NCT02488720)
A4 (NCT02008357)
TRAILBLAZER-ALZ 3 (NCT05026866)
TRAILBLAZER-ALZ 2 (NCT04437511)
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Yao Hsien Huang
- Molecule(s): Not Applicable
Demographic Profile, Treatment Patterns, and HealthcareResource Use of Mild Cognitive Impairment and Alzheimer’s Disease in Taiwan
Trial(s) Overview:
Not Applicable
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Vikas Kotari
- Molecule(s): Donanemab, Flortaucipir
Regional Tau Quantification Methodologies in Early Symptomatic Participants with Presence of Tau Pathology
Trial(s) Overview:
TRAILBLAZER-ALZ (NCT03367403)
TRAILBLAZER-ALZ 2 (NCT04437511)
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Alette Wessels
- Molecule(s): Donanemab
Clinical Relevance of Disease-Modifying Therapies for Alzheimer’s Disease
Trial(s) Overview:
TRAILBLAZER-ALZ 2 (NCT04437511)
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Drew Spargo
- Molecule(s): Not Applicable
The Economic Value of Plasma P-tau217 Testing for Patients Presenting with Cognitive Impairment in the United States
Trial(s) Overview:
Not Applicable
SUNDAY
- Disease State: Alzheimer's Disease
- Presented by: Jiawei Xin
- Molecule(s): Not Applicable
A Real-World Survey of the Diagnostic Journey, Current Treatment, and Burden of Mild Cognitive Impairment or Dementia Due to Alzheimer’s Disease in China
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Juan E Maldonado Weng
- Molecule(s): Not Applicable
Spatially Resolved Transcriptomics/Proteomics Identifies Increased Inflammatory Response in Alzheimer’s Disease Patients with Cerebral Amyloid Angiopathy
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Ian Kennedy
- Molecule(s): Donanemab, Flortaucipir
Association of Occipital Amyloid PET Burden with ARIA-E: Exploratory Analyses in Three Clinical Trials of Donanemab
Trial(s) Overview:
TRAILBLAZER-ALZ (NCT03367403)
TRAILBLAZER-ALZ 2 (NCT04437511)
TRAILBLAZER-ALZ 4 (NCT05108922)
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Hong Wang
- Molecule(s): Donanemab
Modified Titration of Donanemab Reduced ARIA-E risk and Maintained Amyloid Reduction: 18-Month Results from TRAILBLAZER-ALZ 6
Trial(s) Overview:
TRAILBLAZER-ALZ 6 (NCT05738486)
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Kay Hoong Chow
- Molecule(s): Not Applicable
Quantifying Natural Amyloid Plaque Accumulation Using DiseasePprogression Modeling with ADNI, BioFINDER, and LEARN Datasets
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: John Tzaferis
- Molecule(s): Not Applicable
Engagement of Amyloid-Targeting Antibodies on Native Human and Murine Cerebral Amyloid Angiopathy CAA Containing Vessels
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Zachary Sheff
- Molecule(s): Not Applicable
Presence and Impact of Neuropsychiatric Symptoms in Preclinical Alzheimer’s Disease
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Mark Mintun
- Molecule(s): Donanemab
Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety from the TRAILBLAZER‐ALZ 2 Long-Term Extension
Trial(s) Overview:
TRAILBLAZER-ALZ 2 (NCT04437511)
To receive the latest science and innovation, please be sure to follow us on Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)